trial · primary record
20 mg 102D-6 dry suspension
Influenza, Human
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 570 |
| Primary completion | 2027-03-30 |
| Primary endpoint | Phase II:Viral RNA negative conversion time Phase III:time to alleviation of influenza symptoms |
| Registry ID | NCT07893847 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:14.492Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07893847
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.